I think one can look at what is happening with regard to biologicals in India and extrapolate it to ROW.
I will use Trastuzumab as an example.
Biocon was first to launch Trastuzumab generic in India in 2014 and at that time, it was priced just 15% below innovator. Now, many companies make Trastuzumab and hence, there is severe price erosion - to the tune of 60 - 70%.
Another phenomenon which has happened in India is launch of government sponsored health schemes - this has led to increase in volumes, but organization of practice - ie rather than scattered practices and hence drug usage, institutionalization of practice and tender based drug procurement.
It is pertinent to ask the management about their market share in India for Trastuzumab. As per my knowledge, there is tough price war and Reliance is grabbing progressively larger share of tender based procurement.
Since i am related to Oncology field, i can talk about products related to Oncology ie, Trastuzumab, Bevacizumab, Filgrastim, Peg-Filgrastim etc.
Although Biocon was very early in the race, US and EU regulatory pathways for approval of Biologicals took long time to get established and approve the first product. But once the pathways got established, it became easier to get approved as happens with chemical based generic pharma.
It is not that Biocon may not create wealth. However, IMHO, it faces an uphill task with progressive commoditization.
I am attaching two articles to emphasize the point that Biosimilars is an extremely competitive market in USA - the most lucrative pharma market in the World.
An article about Pfizer biosimilar revenues dated 3rd February 2021 where there is competitive landscape / Market share data of Rituximab and Trastuzumab for H1 2020 which may be useful.
Another article is about the threat of innovation to biosimilar story -
Coherus Biosciences had 20% market share in PegFilgrastim before it got disrupted by launch of Onpro - An on body injector by Amgen
It also mentions launch of Pegfilgrastim biosimilar by Pfizer in December 2020 - indicating more competition
Moreover, Both Trastuzumab and Rituximab have been already approved in Subcutaneous Forms - making the administration convenient and short - Another innovation which will hamper biosimilar growth.
These are some of my thoughts about competitive landscape of biologicals based on my knowledge. Kindly take them as input to the forum rather than any prediction about Biocon future performance.
Addition: If i understand correctly, there is no 6 month exclusivity as happens with non biological drugs like pomalidomide (NATCO) in case of biosimilars.